New York Times July 17, 2025: This FDA panel hosted by Commissioner Makary ignores evidence of the serious risks of hormone therapy for menopause, such as breast cancer, endometrial cancer, and stroke. Instead it focuses only on benefits, relying on misleading and erroneous information. The panel wants to remove the “black box” warning that tells women about the risks. No public comment was allowed at the meeting. We would have disagreed strongly, except with the issue of whether hormonal cream used in the vagina should not have the same black box warning as the hormonal pills.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
FDA Panel to Revisit Menopausal Hormone Therapy
Politico; July 15, 2025: This article describes the FDA panel on the risks and benefits of hormone therapy for menopause: breast cancer, heart disease,stroke, dementia. Zuckerman points out that the panel is one-sided, ignoring data on risks and not allowing public comments from patients or experts to ask questions or describe studies indicating cancer and other serious risks.
Read More »RFK Jr.’s tough talk on corporate influence isn’t adding up in practice
Environmental Health Network, June 26, 2025: EHN reports that HHS and RFK Jr. claim to stop conflicts of interest, but industry influence and other conflicts remain, as explained by NCHR’s Diana Zuckerman.
Read More »RFK Jr.’s Planned Assault on Corporate Influence Is Clashing With Reality
June 26, 2025: NOTUS news article gives numerous examples from experts who agree with RFK Jr and Makary criticisms of corporate influence on health, but say HHS plans to reduce conflicts of interest are ineffective and FDA remains overly influenced by industry.
Read More »Biotech pauses trial after second patient death linked to gene therapy
The Washington Post, June 17, 2025; Sarepta restricts Elevidys gene therapy for non-ambulatory Duchenne muscular dystrophy patients after second death. We point out that FDA flexibility “does no favor” to patients who may die from using a questionable treatment. Elevidys costs $3.2 million per patient.
Read More »